Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 401–500 of 1,000
Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs
Gardiner, P., Cox, R. J., & Grime, K. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.087163 · Cited by 32
“The delivery of compounds into clinical drug development with optimal pharmacokinetics (PK) is important to overall clinical success (Schuster et al., 2005; Cook et al., 2014) and consequently the ability to accurately predict human PK prior to clinical investment is of high importance (Di et al.”
BackgroundScott, J., Sueiro-Olivares, M., Thornton, B. P., Owens, R. A., Muhamadali, H., Fortune‐Grant, R., Thomson, D. D., Thomas, R., Hollywood, K. A., Doyle, S., et al. (2020) · mBio · doi:10.1128/mbio.01985-20 · Cited by 34
“II compared to only 43% of projects without such extra target validation (24).”
BackgroundNetwork and pathway expansion of genetic disease associations identifies successful drug targets
MacNamara, A., Nakić, N., Olama, A. A. A., Guo, C., Sieber, K. B., Hurle, M. R., & Gutteridge, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-77847-9 · Cited by 33
Highway to Success—Developing Advanced Polymer Therapeutics
Ashford, M. B., England, R., & Akhtar, N. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000285 · Cited by 35
Drug Screening, Oral Bioavailability and Regulatory Aspects: A Need for Human Organoids
Zietek, T., Boomgaarden, W., & Rath, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081280 · Cited by 35
Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics
Montero‐Melendez, T., Boesen, T. P., & Jonassen, T. E. N. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101603 · Cited by 38
Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model
Everts, M., Cihlář, T., Bostwick, J. R., & Whitley, R. J. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104533 · Cited by 32
“For example, a recent review analyzed the pipeline at a large pharmaceutical company and the reasons for program failure there (50).”
BackgroundMethodInfluentialFabre, K. M., Delsing, L., Hicks, R., Colclough, N., Crowther, D. C., & Ewart, L. C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.009 · Cited by 32
Bujar, M., McAuslane, N., Walker, S., & Salek, S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00189 · Cited by 34
“…has benefitted from more structured decision making is portfolio management, where companies have been using frameworks (Sharpe and Keelin, 1998; Cook et al., 2014) as well as quantitative methods and algorithms (Hassanzadeh et al., 2011; Jekunen, 2014) in order to analyze and optimize the…”
MethodChromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases
Martin, P., Ding, J., Duffus, K., Gaddi, V. P., McGovern, A., Ray-Jones, H. F., Yarwood, A., Worthington, J., Barton, A. C., & Orozco, G. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214649 · Cited by 29
A Systems Toxicology Approach for the Prediction of Kidney Toxicity and Its Mechanisms In Vitro
Ramm, S., Todorov, P. V., Chandrasekaran, V., Dohlman, A. B., Monteiro, M. B., Pavkovic, M., Muhlich, J. L., Shankaran, H., Chen, W. W., Mettetal, J. T., et al. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz021 · Cited by 34
Prioritizing target-disease associations with novel safety and efficacy scoring methods
Failli, M., Paananen, J., & Fortino, V. (2019) · Scientific Reports · doi:10.1038/s41598-019-46293-7 · Cited by 35
Cryogel-Integrated Biochip for Liver Tissue Engineering
Boulais, L., Jellali, R., Pereira, U., Leclerc, É., Bencherif, S. A., & Legallais, C. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00425 · Cited by 31
Raster plots machine learning to predict the seizure liability of drugs and to identify drugs
Matsuda, N., Odawara, A., Kinoshita, K., Okamura, A., Shirakawa, T., & Suzuki, I. (2022) · Scientific Reports · doi:10.1038/s41598-022-05697-8 · Cited by 31
Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells
Fuh, F. K., Looney, C., Li, D., Poon, K. A., Dere, R. C., Danilenko, D. M., McBride, J., Reed, C., Chung, S., Zheng, B., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13697 · Cited by 31
“This attrition rate has largely been attributed to lack of efficacy and highlights the need for understanding MOA and pharmacological activity at early stages of development (Cook et al., 2014).”
BackgroundOpportunities to Apply the 3Rs in Safety Assessment Programs
Sewell, F. R., Edwards, J., Prior, H. M., & Robinson, S. (2016) · ILAR Journal · doi:10.1093/ilar/ilw024 · Cited by 35
“…causes of attrition throughout the development pipeline are cardiovascular and liver toxicities leading to the need for the development of screens (animal and nonanimal) that are more predictive of these liabilities (Cook et al. 2014; Hornberg et al. 2014; Redfern et al. 2010; Waring et al. 2015).”
BackgroundHowley, E., Bestwick, M., Fradley, R. L., Harrison, H., Leveridge, M., Okada, K., Fieldhouse, C., Farnaby, W., Canning, H. E., Sykes, A. P., et al. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2367-9 · Cited by 30
Recellularized Native Kidney Scaffolds as a Novel Tool in Nephrotoxicity Screening
Fedecostante, M., Westphal, K. G. C., Buono, M. F., Romero, N. S., Wilmer, M. J. G., Kerkering, J., Baptista, P. M., Hoenderop, J. G. J., & Masereeuw, R. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.080721 · Cited by 32
“A portion of newly developed pharmaceuticals fail during the preclinical and clinical phases as a result of nephrotoxicity (Cook et al., 2014).”
Elephants, Parkinson's Disease, and Proof‐of‐Concept Clinical Trials
Cedarbaum, J. M. (2018) · Movement Disorders · doi:10.1002/mds.27398 · Cited by 31
Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems
Svensson, E., von Mentzer, U., & Stubelius, A. (2023) · ACS Materials Au · doi:10.1021/acsmaterialsau.3c00073 · Cited by 36
Highly scalable and standardized organ-on-chip platform with TEER for biological barrier modeling
Nguyen, H.-T., Rissanen, S.-L., Peltokangas, M., Laakkonen, T., Kettunen, J., Barthod, L., Sivakumar, R., Palojärvi, A., Junttila, P., Talvitie, J., et al. (2024) · Tissue Barriers · doi:10.1080/21688370.2024.2315702 · Cited by 31
“One of the main reasons for this failure is the poor predictivity of current preclinical models 1–4 .”
Peters, S. A., Petersson, C., Blaukat, A., Halle, J.-P., & Dolgos, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.002 · Cited by 30
CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets
Rubbini, D., Cornet, C., Terriente, J., & Donato, V. D. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220926920 · Cited by 37
“In that sense, the success of a potential new therapeutic drug is directly proportional to the accuracy of toxicity and efficacy predictions during the preclinical phase.(7,9) Therefore, the identification and validation of drugs in the most suitable preclinical models are crucial to determining their later success as…”
BackgroundVizirianakis, I. S., Mystridis, G. A., Avgoustakis, K., Fatouros, D. G., & Spanakis, M. (2016) · Oncology Reports · doi:10.3892/or.2016.4575 · Cited by 39
“the genetic polymorphism of various gene alleles referring to drug metabolizing enzymes, transporters and receptors (21-32).”
BackgroundApplication of hepatocyte-like cells to enhance hepatic safety risk assessment in drug discovery
Williams, D. P. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2017.0228 · Cited by 29
mGluR2 positive allosteric modulators: an updated patent review (2013–2018)
Trabanco, A. A., Bartolomé, J. M., & Cid, J. M. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1637421 · Cited by 32
Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes
Abi‐Gerges, N., Indersmitten, T., Truong, K., Nguyen, W., Ratchada, P., Nguyen, N., Page, G., Miller, P. E., & Ghetti, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-64657-2 · Cited by 30
Śmietana, K., Ekstrom, L. B., Jeffery, B., & Møller, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4650 · Cited by 29
An update: emerging drugs for tinnitus
Cederroth, C. R., Dyhrfjeld‐Johnsen, J., & Langguth, B. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1555240 · Cited by 29
“identification is also highlighted in a recent report from AstraZeneca, in which the reason for study failures were analyzed [114].”
BackgroundTowards a hit for every target
Rees, S., Gribbon, P. M., Birmingham, K. E., Janzen, W. P., & Pairaudeau, G. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.19 · Cited by 29
Emerging In Vitro Systems to Screen and Predict Drug-Induced Kidney Toxicity
Nieskens, T. T. G., & Sjogren, A.-K. M. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.12.009 · Cited by 29
Strategies to Address Challenges in Neuroscience Drug Discovery and Development
O’Donnell, P., Rosen, L. B., Alexander, R., Murthy, N. V., Davies, C. H., & Ratti, E. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz027 · Cited by 31
“In addition, a greater focus on project quality and deeper biological understanding is needed (Cook et al., 2014).”
BackgroundSelf-citationRouillard, A. D., Hurle, M. R., & Agarwal, P. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006142 · Cited by 31
“One possible explanation for these failures is sub-optimal target selection (3).”
BackgroundGupta, I., Cassara, A. M., Tarotin, I., Donegà, M., Miranda, J. A., Sokal, D. M., Ouchouche, S., Dopson, W. J., Matteucci, P. B., Neufeld, E., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01299-0 · Cited by 34
Wang, D. Y. Q., Hensman, J. J., Kutkaite, G., Toh, T. S., Galhoz, A., GDSC Screening Team, Lightfoot, H. W., Yang, W., Soleimani, M., Barthorpe, S., et al. (2020) · eLife · doi:10.7554/elife.60352 · Cited by 30
“, 2011), whilst not in colorectal cancer patients due to feedback activation of ERK-signalling mediated via EGFR (Corcoran et al., 2018; Prahallad et al., 2012).”
BackgroundInfluentialThe evolution and history of gene editing technologies
Randhawa, S., & Sengar, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.002 · Cited by 39
Petersson, C., Zhou, X., Berghausen, J., Cebrián, D. Á., Davies, M., DeMent, K., Eddershaw, P. J., Riedmaier, A. E., Leblanc, A. F., Manveski, N., et al. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00735-9 · Cited by 27
Wong, H., Bohnert, T., Damian-Iordache, V., Gibson, C., Hsu, C.-P., Krishnatry, A. S., Liederer, B. M., Lin, J., Lu, Q., Mettetal, J. T., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.04.015 · Cited by 27
Nizamoglu, M., Joglekar, M. M., Almeida, C. R., Larsson‐Callerfelt, A., Dupin, I., Guenat, O. T., Henrot, P., van Os, L., Otero, J., Elowsson, L., et al. (2023) · European Respiratory Review · doi:10.1183/16000617.0042-2023 · Cited by 40
Fukushima, K., Miura, Y., Sawada, K., Yamazaki, K., & Ito, M. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115610055 · Cited by 31
“However, such assays using rodent neurons have limitations in predicting the clinical efficacy and neurotoxicity of the candidates due to species differences.(8,9) Thus, using human neurons is a solution to overcome the issue.”
BackgroundValue of shared preclinical safety studies – The eTOX database
Briggs, K. A., Barber, C., Cases, M., Marc, P., & Steger‐Hartmann, T. (2014) · Toxicology Reports · doi:10.1016/j.toxrep.2014.12.004 · Cited by 28
“Many of these compounds fail during the early preclinical phase and never make it into clinical trials or reach the market [1,2].”
BackgroundBueters, T., Gibson, C. R., & Visser, S. A. G. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.143 · Cited by 27
Cancer drug discovery: recent innovative approaches to tumor modeling
Lovitt, C. J., Shelper, T., & Avery, V. M. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1214562 · Cited by 31
“A recent report from AstraZeneca’s drug development program highlighted the low confidence in preclinical cancer models as a critical area leading to unsuccessful project completion [1].”
BackgroundIn Situ Target Engagement Studies in Adherent Cells
Axelsson, H., Almqvist, H., Otrocka, M., Vallin, M., Lundqvist, S., Hansson, P., Karlsson, U., Lundbäck, T., & Seashore-Ludlow, B. A. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b01079 · Cited by 30
High-throughput metabolism-induced toxicity assays demonstrated on a 384-pillar plate
Yu, K., Kang, S., Hong, S., & Lee, M. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2249-1 · Cited by 27
Farouk, F., & Shamma, R. N. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201800213 · Cited by 31
Bhatt, S., Northcott, C. A., Wisialowski, T. A., Li, D., & Steidl-Nichols, J. V. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz035 · Cited by 30
Roberts, R. A., Authier, S., Mellon, R. D., Morton, M. J., Suzuki, I., Tjalkens, R. B., Valentin, J., & Pierson, J. B. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa167 · Cited by 28
“Convulsants have been assessed using MEAs and complex cultures of rodent CNS tissue that contain excitatory and inhibitory neurons as well as glia, cultured neurons, and hippocampus slices (Accardi et al., 2018; Bradley et al., 2018; Bradley and Strock, 2019; Fan et al., 2019; Frega et al., 2012; Koerling et al., 2019…”
BackgroundInfluentialSaavedra, L., Wallace, K., Freudenrich, T. M., Mall, M., Mundy, W. R., Davila, J., Shafer, T. J., Wernig, M., & Haag, D. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab008 · Cited by 30
Yanagida, S., Satsuka, A., Hayashi, S., Ono, A., & Kanda, Y. (2021) · The Journal of Toxicological Sciences · doi:10.2131/jts.46.359 · Cited by 27
Recent Advances in Brain Organoid Technology for Human Brain Research
Jeong, E., Choi, S., & Cho, S. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c17467 · Cited by 29
Zhou, S., Sosina, O. A., Bovijn, J., Laurent, L., Sharma, V., Akbari, P., Forgetta, V., Jiang, L., Kosmicki, J. A., Banerjee, N., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01444-5 · Cited by 32
af Rosenschöld, M. M., Johannesson, P., Nikitidis, A., Tyrchan, C., Chang, H., Rönn, R., Chapman, D., Ullah, V., Nikitidis, G., Glader, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00555 · Cited by 26
A Historical View and Vision into the Future of the Field of Safety Pharmacology
Bass, A. S., Hombo, T., Kasai, C., Kinter, L. B., & Valentin, J. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46943-9_1 · Cited by 31
Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
Potdar, S., Ianevski, F., Ianevski, A., Tanoli, Z., Wennerberg, K., Seashore-Ludlow, B. A., Kallioniemi, O., Östling, P., Aittokallio, T. A., & Saarela, J. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad390 · Cited by 28
Forward or Backward: Lessons Learned from Small Molecule Drugs Approved by FDA from 2012 to 2022
Gu, M., Sun, S., You, Q., & Wang, L. (2023) · Molecules · doi:10.3390/molecules28247941 · Cited by 33
A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System
Zhao, X., Qi, X., Liu, D., Che, X., & Wu, G. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s498729 · Cited by 29
“…successfully translating a small molecule drug from the preclinical proof-of-concept stage to a commercially marketed product is approximately 6%, 170 and even when the risks of development are not taken into account, the complex formulations of nanoparticles and the lengthy process of their…”
Wang, W., Shi, Q., Mattes, W. B., Mendrick, D. L., & Yang, X. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.86 · Cited by 28
Seashore-Ludlow, B. A., & Lundbäck, T. (2016) · SLAS DISCOVERY · doi:10.1177/1087057116659256 · Cited by 26
“Recent metadata from clinical trials indicate that proof of target engagement, alongside the concurrent presence of drug candidate in the desired tissue and validated functional and phenotypic outcomes, is essential for successful clinical trial outcomes.(8,9) Although it is highly relevant to include routine measurem…”
BackgroundThe open targets post-GWAS analysis pipeline
Peat, G., Jones, W., Nuhn, M., Marugán, J. C., Newell, W. R., Dunham, I., & Zerbino, D. R. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa020 · Cited by 24
Toxicogenomics of drug induced liver injury – from mechanistic understanding to early prediction.
Lauschke, V. M. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1894571 · Cited by 29
“In addition to its clinical relevance, hepatotoxicity constitutes a major hurdle in drug development and remains a leading cause of drug failure during both preclinical and clinical stages (Watkins 2011; Cook et al. 2014).”
BackgroundAdvancing drug discovery using the power of the human genome
Heilbron, K., Mozaffari, S. V., Vacic, V., Yue, P., Wang, W., Shi, J., Jubb, A. M., Pitts, S. J., & Wang, X. (2021) · The Journal of Pathology · doi:10.1002/path.5664 · Cited by 27
“Within AstraZeneca from 2005 to 2010, lack of efficacy was responsible for the closure of 57% of phase IIa projects and 88% of phase IIb projects [2].”
BackgroundAI-Driven Decision-Making Applications in Pharmaceutical Sciences
Yingngam, B., Navabhatra, A., & Sillapapibool, P. (2024) · Advances in media, entertainment and the arts (AMEA) book series · doi:10.4018/979-8-3693-0639-0.ch001 · Cited by 39
Investigating Apoptozole as a Chemical Probe for HSP70 Inhibition
Evans, L. E., Cheeseman, M. D., Yahya, N., & Jones, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140006 · Cited by 28
“[1–4] The 2014 report by Astra Zeneca, analyzing their small molecule drug discovery programs over a five year period, found that the primary cause of drug candidates failing clinical trails due to lack of efficacy to be when “pharmacological engagement of a proposed mechanism of action did not result in clinical bene…”
BackgroundClinical potential of oligonucleotide-based therapeutics in the respiratory system
Moschos, S. A., Usher, L., & Lindsay, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.009 · Cited by 28
“, 2012) and subsequent emerging principles in drug development (Cook et al., 2014).”
BackgroundInfluentialAdvances in Predictive Toxicology for Discovery Safety through High Content Screening
Persson, M., & Hornberg, J. J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00248 · Cited by 26
Bocxlaer, K. V., & Croft, S. L. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00343c · Cited by 26
Artificial Intelligence in Drug Safety and Metabolism
Smith, G. F. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_22 · Cited by 30
Hampson, L. V., Holzhauer, B., Bornkamp, B., Kahn, J., Lange, M. R., Luo, W., Singh, P., Ballerstedt, S., & Cioppa, G. D. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2488 · Cited by 29
Application Progress of Organoids in Colorectal Cancer
Luo, L., Ma, Y., Zheng, Y., Su, J., & Huang, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.815067 · Cited by 34
Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury
Carr, D. F., Ayehunie, S., Davies, A., Duckworth, C. A., French, S., Hall, N., Hussain, S. A., Mellor, H. R., Norris, A. M., Park, B. K., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.01.002 · Cited by 27
“(Redfern et al., 2010), gastrointestinal toxicity contributed to 9% of project closures in the clinic (Cook et al., 2014), reinforcing the poor performance of pre-clinical GI toxicity prediction approaches.”
BackgroundBeierlein, J. M., McNamee, L. M., Walsh, M. J., Kaitin, K. I., DiMasi, J. A., & Ledley, F. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.001 · Cited by 24
Kanes, S., Dennie, L., & Perera, P. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s402831 · Cited by 31
Human genetics as a model for target validation: finding new therapies for diabetes
Thomsen, S. K., & Gloyn, A. L. (2017) · Diabetologia · doi:10.1007/s00125-017-4270-y · Cited by 27
“The most common reasons for failure include lack of efficacy and/or unsuitable safety profiles, even in cases where the correct target is engaged [4, 5].”
BackgroundSchuck, R. N., Pacanowski, M. A., Kim-McOlash, S., Madabushi, R., & Zineh, I. (2019) · Clinical and Translational Science · doi:10.1111/cts.12626 · Cited by 24
FAM13A as potential therapeutic target in modulating TGF-β-induced airway tissue remodeling in COPD
Tam, A., Leclair, P., Li, L. V., Yang, C. X., Li, X., Witzigmann, D., Kulkarni, J. A., Hackett, T., Dorscheid, D. R., Singhera, G. K., et al. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00477.2020 · Cited by 26
“This is because the likelihood of success of such therapeutics 430 in Phase II clinical trials is 50 to 100% greater compared to therapeutic targets that are 431 disconnected from genetics (14, 22, 30).”
BackgroundRapid target validation in a Cas9-inducible hiPSC derived kidney model
Shamshirgaran, Y., Jonebring, A., Svensson, A., San, I. V. L. C., Bohlooly‐Y, M., Firth, M. A., Woollard, K. J., Hofherr, A., Rogers, I. M., & Hicks, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-95986-5 · Cited by 26
Ishibashi, Y., Odawara, A., Kinoshita, K., Okamura, A., Shirakawa, T., & Suzuki, I. (2021) · Toxicological Sciences · doi:10.1093/toxsci/kfab116 · Cited by 24
Chunduri, V., & Maddi, S. (2022) · ADMET & DMPK · doi:10.5599/admet.1513 · Cited by 59
“Drug-induced toxicity can occur in various organs and tissues in the body and causes acute injury [163].”
BackgroundClinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD
Bihlet, A. R., Karsdal, M. A., Bay‐Jensen, A., Read, S., Kristensen, J. H., Sand, J. M. B., Leeming, D. J., Andersen, J. R., Lange, P., & Vestbo, J. (2015) · CHEST Journal · doi:10.1378/chest.15-0296 · Cited by 24
Drug development for breast, colorectal, and non–small cell lung cancers from 1979 to 2014
Nixon, N. A., Khan, O. F., Imam, H., Tang, P. A., Monzon, J. G., Li, H., Sun, G. R., Ezeife, D. A., Parimi, S., Dowden, S. D., et al. (2017) · Cancer · doi:10.1002/cncr.30919 · Cited by 24
“Previous studies have consistently shown that among drugs failing in later stages of development, there is a lack of biomarker stratification in comparison with those drugs that succeed.(24,25) Although targeted agents and biomarker selection may result in more efficient drug development, it limits the population in w…”
ResultCan octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
Blaskovich, M. A. T., Pitt, M. E., Elliott, A. G., & Cooper, M. A. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1483240 · Cited by 24
“A significant proportion of investigational drugs fail in clinical trials due to nephrotoxicity, with an analysis of the AstraZeneca pipeline showing 9% of the 52% clinical failures due to renal issues (and 8% of the 82% of projects failing at the preclinical stage) [126].”
BackgroundThiel, C., Smit, I. A., Baier, V., Cordes, H., Fabry, B. A., Blank, L. M., & Kuepfer, L. (2018) · npj Systems Biology and Applications · doi:10.1038/s41540-018-0062-3 · Cited by 23
“A truly mechanistic assessment of physiological and biochemical processes governing the drug exposure and the resulting drug action is hence beneficial to improve the still high attrition rates of new drug candidates.(1) However, such an in-depth understanding is hard to achieve given the complexity of physiological p…”
BackgroundSeashore-Ludlow, B. A., Axelsson, H., Almqvist, H., Dahlgren, B., Jönsson, M., & Lundbäck, T. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b01057 · Cited by 25
Hu, R., Zhou, T., Li, B., Kwok, R. T. K., Shen, J., Qin, A., & Tang, B. Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119658 · Cited by 24
Advancing predictive toxicology: overcoming hurdles and shaping the future
Masarone, S., Beckwith, K. V., Wilkinson, M. R., Tuli, S., Lane, A., Windsor, S., Lane, J. S., & Hosseini-Gerami, L. (2025) · Digital Discovery · doi:10.1039/d4dd00257a · Cited by 31
Qiu, X., Zhou, X., Miao, Y., & Li, B. (2018) · Toxicology Research · doi:10.1039/c8tx00095f · Cited by 27
Al-Amin, R. A., Gallant, C. J., Muthelo, P. M., & Landegren, U. D. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02225 · Cited by 23
Arrhythmogenic and antiarrhythmic actions of late sustained sodium current in the adult human heart
Ton, A. T., Nguyen, W., Sweat, K., Miron, Y., Hernandez, E., Wong, T., Geft, V., Macias, A., Espinoza, A., Truong, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91528-1 · Cited by 25
Tosca, E. M., Bartolucci, R., Magni, P., & Poggesi, I. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1931114 · Cited by 24
[11C]HCN Radiochemistry: Recent Progress and Future Perspectives
Xu, Y., & Qü, W. (2021) · European Journal of Organic Chemistry · doi:10.1002/ejoc.202100651 · Cited by 28
Naga, D., Muster, W., Musvasva, E., & Ecker, G. F. (2022) · Journal of Cheminformatics · doi:10.1186/s13321-022-00603-w · Cited by 25
Chan, J. O. Y., Moullet, M., Williamson, B., Arends, R. H., & Reddy, V. P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.874606 · Cited by 24
“AstraZeneca’s “5R” framework aims to accelerate drug development by identifying the right target, the right patient, the right tissue, the right safety and the right commercial potential early in the drug discovery process (Cook et al., 2014).”
BackgroundFrom Financialisation to Innovation in UK Big Pharma: AstraZeneca and GlaxoSmithKline
Tulum, Ö., Andreoni, A., & Lazonick, W. H. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009278140 · Cited by 32
Understanding drug targets: no such thing as bad news
Roberts, R. A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.028 · Cited by 23
Rodrigues, D., de Souza, T. M., Jennen, D. G. J., Lemmens, L., Kleinjans, J. C. S., & de Kok, T. M. C. M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.004 · Cited by 25
Webster, J. D., Santagostino, S. F., & Foreman, O. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03101-y · Cited by 25
“The causes for drug attrition are varied and include lack of efficacy, safety concerns, inadequate pharmacokinetics or pharmacodynamics, and market forces, such as the competitive landscape (Cook et al. 2014; Thomas et al. 2016).”
BackgroundBentwich, I. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103515 · Cited by 22
Drug-induced kidney injury: challenges and opportunities
Connor, S., Roberts, R. A., & Tong, W. (2024) · Toxicology Research · doi:10.1093/toxres/tfae119 · Cited by 29
Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology
Valentin, J., & Leishman, D. J. (2025) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2025.105795 · Cited by 27
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.